Nektar Therapeutics (NKTR) Liabilities from Discontinued Operations (2024)
Nektar Therapeutics (NKTR) posted quarterly Liabilities from Discontinued Operations of 5125000.0 for Q3 2024.
Powered by 
Analysis
Nektar Therapeutics (NKTR) Liabilities from Discontinued Operations (2024) Analysis & Trends
Nektar Therapeutics' Liabilities from Discontinued Operations history runs 1 years deep, the most recent figure standing at 5125000.0 for Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn |